Eisai Co. Ltd (ESALY.PK) and Biogen Inc. (BIIB) on Friday said the U.S. Food and Drug Administration has extended by three months the review of LEQEMBI IQLIK as a starting dose for the treatment of early Alzheimer's disease.
The new Prescription Drug User Fee Act (PDUFA) action date is August 24, 2026.
The FDA requested additional information during the review process and has not raised any concerns about the drug's approvability as a starting dose, the companies said.
LEQEMBI has been approved in more than 50 countries for the treatment of early Alzheimer's disease.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.